Pakistan Drug Firms Note Lower Investment As Regulatory Policy Wavers
This article was originally published in PharmAsia News
Pakistan's drug makers note investment in their local pharmaceutical industry has declined over the past two years as the government continued to operate without a regulatory chief executive to set policy.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.